Casein Kinase

Kinase

Casein Kinase

Casein Kinase Isoform Specific Products:

Casein Kinase Related Products (168)
Antibodies (5)
Casein Kinase Isoform Comparison

By Effects:	Ligand (1) Inhibitors (149) Degraders (5) Antagonist (1) Activator (1) Chemical (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-15535

DMAT	Inhibitor	98.09%
DMAT is a potent and specific CK2 inhibitor with an IC₅₀ value of 130 nM.

HY-139004

SGC-CK2-1	Inhibitor	99.67%
SGC-CK2-1 is a highly potent, ATP-competitive, and cell-active CK2 chemical probe with exclusive selectivity for both human CK2 isoforms, with IC₅₀s of 36 and 16 nM for CK2α and CK2α′respectively in the nanoBRET assay. SGC-CK2-1 can be used for the research of neurodegenerative diseases.

HY-12774

IC261	Inhibitor	99.54%
IC261 is a selective, ATP-competitive CK1 inhibitor, with IC₅₀s of 1 μM, 1 μM, 16 μM for Ckiδ, Ckiε and Ckiα1, respectively.

HY-120675

SSTC3	Activator	98.65%
SSTC3 is a casein kinase 1α (CK1α) activator (K_d = 32 nM) that inhibits WNT signaling (EC₅₀ = 30 nM). SSTC3 exhibits minimal gastrointestinal toxicity compared to other classes of WNT inhibitors.

HY-108642B

AMG-548 dihydrochloride	Inhibitor	99.91%
AMG-548 dihydrochloride, an orally active and selective p38α inhibitor (K_i=0.5 nM), shows slightly selective over p38β (K_i=36 nM) and >1000 fold selective against p38γ and p38δ. AMG-548 dihydrochloride is also extremely potent in the inhibition of whole blood LPS stimulated TNFα (IC₅₀=3 nM). AMG-548 dihydrochloride inhibits Wnt signaling by directly inhibiting Casein kinase 1 isoforms δ and ε.

HY-115519

(E/Z)-GO289	Inhibitor	99.60%
(E/Z)-GO289 is a potent and selective casein kinase 2 (CK2) inhibitor (IC₅₀=7 nM). (E/Z)-GO289 strongly lengthens circadian period. (E/Z)-GO289 exhibits cell type–dependent inhibition of cancer cell growth that correlated with cellular clock function.

HY-10456

TAK-715	Inhibitor	99.76%
TAK-715 is an orally active and potent p38 MAPK inhibitor with IC₅₀s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits casein kinase I (CK1δ/ε) to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model.

HY-12443

PF-5006739	Inhibitor	99.56%
PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC₅₀s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity. PF-5006739 attenuats opioid agent-seeking behavior in a rodent operant reinstatement model in animals in a dose-dependent manner. PF-5006739 improves glucose tolerance in both diet-induced obesity (DIO) and genetic (ob/ob) mice models of obesity.

HY-133028

CKI-7 free base	Inhibitor	99.80%
CKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC₅₀ of 6 μM and a K_i of 8.5 μM. CKI-7 free base is a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect on casein kinase II and other protein kinases.

HY-145939

BAY-888	Inhibitor	98.35%
BAY-888 is an orally active CSNK1A1 and CSNK1D inhibitor with IC₅₀ of 1.5 nM and 5.5 nM, respectively. BAY-888 has antitumor activity.

HY-129571

BioE-1115	Inhibitor	99.56%
BioE-1115 is a highly selective and potent PAS kinase (PASK) inhibitor with an IC₅₀ of ~4 nM. BioE-1115 is also a potent casein kinase 2α inhibitor with an IC₅₀ of ~10 μM.

HY-125865

Casein
Casein is an orally active phosphoprotein that can be separated into various electrophoretic components, such as α₂-Casein, κ-Casein, β-casein, and γ-casein. Casein has also been blended and grafted with other polymers, cross-linkers, or monomers to improve its functional properties. Casein enhances calcium absorption and reduces the extent of fissure as well as smooth-surface caries. Casein promotes proliferation of prostate cancer. Casein has various applications in the paper, leather, textile, and food industries, serving as coatings, adhesives, and packaging materials.

HY-135906

CK2/ERK8-IN-1	Inhibitor	≥99.0%
CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) (K_i of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC₅₀s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1, HIPK2 (homeodomain-interacting protein kinase 2), and DYRK1A with K_is of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy.

HY-15479

TTP 22	Inhibitor	98.40%
TTP 22 is a potent CK2 inhibitor, with an IC₅₀ of 100 nM and a K_i of 40 nM.

HY-10108A

LY294002 hydrochloride	Inhibitor	99.93%
LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC₅₀ values of 0.5, 0.57, and 0.97 μM for P110α, P110δ and P110β, respectively. LY294002 hydrochloride also inhibits CK2 with an IC₅₀ of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research.

HY-114858

Epiblastin A	Inhibitor	99.51%
Epiblastin A is an ATP competitive casein kinase 1 (CK1) inhibitor with IC₅₀s of 8.9, 0.5, and 4.7 µM for CK1α, CK1δ, and CK1 ɛ, respectively. Epiblastin A induces reprogramming of epiblast stem cells into embryonic stem cells by inhibition of CK1.

HY-145940

BAY-204	Inhibitor	99.94%
BAY-204 is an inhibitor of Casein kinase 1 alpha and delta (CSNK1α and δ) useful for the research of proliferative disorders.

HY-119751

Hematein	Inhibitor
Hematein is a oxidation product of hematoxylin acted as a dye. Hematein is an allosteric casein kinase II inhibitor with an IC₅₀ of 0.74 μM. Hematein inhibits Akt/PKB Ser129 phosphorylation, the Wnt/TCF pathway and increases apoptosis in lung cancer cells.

HY-111820

CK1-IN-1	Inhibitor	99.35%
CK1-IN-1 is a casein kinase 1 (CK1) inhibitor extracted from patent WO2015119579A1, compound 1c, has IC₅₀s of 15 nM, 16 nM, 73 nM for CK1δ, and CK1ε, p38σ MAPK, respectively.

HY-120084

BTX161	Inhibitor	99.20%
BTX161, a thalidomide analog, is an effective CKIα degrader. BTX161 mediates human AML cell CKIα degradation more effectively than lenalidomide and activates the DNA damage response (DDR) and p53, while stabilizing p53 antagonist MDM2.

Silmitasertib		CK2α, IC₅₀: 1 nM CK2α', IC₅₀: 1 nM	99.94%
IWP-2	CK1δ, IC₅₀: 40 nM		99.93%
Emodin		CK2α Wild-type, IC₅₀: 5.9 μM (at ATP concentration is 50 μM) CK2α Wild-type, IC₅₀: 1.4 μM (at ATP concentration is 10 μM)	99.25%
Ellagic acid		CK2, IC₅₀: 40 nM	99.46%
CK1δ-IN-10	CK1δ, IC₅₀: 0.255 μM
QXG-6442	CK1α, DC₅₀: 5.7 nM
D4476	CK1, IC₅₀: 0.3 μM		99.94%
PF-670462 dihydrochloride	CKIδ, IC₅₀: 14 nM		99.96%
Silmitasertib sodium salt		CK2α, IC₅₀: 1 nM CK2α', IC₅₀: 1 nM	99.92%
TBB		CK2, IC₅₀: 0.15 μM (Human CK2)	98.83%
TMX-4116	CK1α		99.76%
BTX-A51	CKIα		98.58%
FPFT-2216	CK1α		99.75%
SR-3029	CKIδ, IC₅₀: 44 nM		99.73%
PF-4800567	CKIδ, IC₅₀: 711 nM		99.69%
DMAT		CK2, IC₅₀: 0.13 μM (Human CK2)	98.09%
SGC-CK2-1		CK2α, IC₅₀: 36 nM CK2α', IC₅₀: 16 nM	99.67%
IC261	CKIδ, IC₅₀: 1 μM CkIα1, IC₅₀: 16 μM		99.54%
AMG-548 dihydrochloride	CK1		99.91%
TAK-715	CK1δ CK1ε		99.76%
PF-5006739	CK1δ, IC₅₀: 3.9 nM		99.56%
CKI-7 free base	CK1, IC₅₀: 6 μM CK1, Ki: 8.5 μM		99.80%
BioE-1115		CK2α, IC₅₀: 10 μM	99.56%
CK2/ERK8-IN-1		CK2, IC₅₀: 0.5 μM CK2, Ki: 0.25 μM	≥99.0%
TTP 22		CK2, IC₅₀: 100 nM	98.40%
LY294002 hydrochloride		CK2, IC₅₀: 0.098 μM CK2α2, IC₅₀: 3.869 μM	99.93%
Hematein		CKII, IC₅₀: 0.74 μM
CK1-IN-1	CKIδ, IC₅₀: 15 nM		99.35%
Casein Kinase inhibitor A86	CKIα		99.26%
TA-01	CKIδ, IC₅₀: 6.8 nM		99.86%
MU1742	CKIδ		99.74%
Casein Kinase 2 Substrate Peptide		CK2	98.47%
CK2 inhibitor 2		CK2, IC₅₀: 0.66 nM	98.51%
NCC007	CKIα, IC₅₀: 1.8 μM CKIδ, IC₅₀: 3.6 μM		99.73%
LH846	CKIδ, IC₅₀: 290 nM CKIα, IC₅₀: 2.5 μM		98.18%
TMX-4113	CK1α		99.08%
TBCA		CK2, IC₅₀: 110 nM CK2, Ki: 77 nM	99.45%
Longdaysin	CKIα, IC₅₀: 5.6 μM CKIδ, IC₅₀: 8.8 μM		99.83%
ON 108600		CK2α2, IC₅₀: 0.005 μM CK2α1, IC₅₀: 0.05 μM	99.73%
MRT00033659	CKIδ, IC₅₀: 0.9 μM		99.77%
PI-828		CK2, IC₅₀: 149 nM CK2α2, IC₅₀: 1.127 μM	99.62%
CK1-IN-2	CKIα, IC₅₀: 123 nM		99.54%
BRD4/CK2-IN-1		CK2, IC₅₀: 230 nM	98.62%
AMG-548	CK1		≥99.0%
Quinalizarin		CK2, Ki: ~50 nM CK2, IC₅₀: 110 nM
SRPIN803		CK2, IC₅₀: 203 nM	99.17%
(R)-DRF053 dihydrochloride	CK1, IC₅₀: 14 nM		99.30%
A-3 hydrochloride	CK1, Ki: 80 μM	CK2, Ki: 5.1 μM	99.75%
Casein kinase 1δ-IN-1	CKIδ		99.91%
Casein kinase 1δ-IN-9	CK1δ		≥98.0%
IQA		CK2
Casein Kinase II Receptor Peptide		CK2, Km: 500 μM
CKI-7	CK1, IC₅₀: 6 μM CK1, Ki: 8.5 μM
Casein kinase 1δ-IN-27	CK1ε, IC₅₀: 9.41 nM CK1δ, IC₅₀: 16.5 nM CK1α, IC₅₀: 22 nM
CK2-IN-3		CK2α, IC₅₀: 1.51 μM CK2α', IC₅₀: 7.64 μM
Ellagic acid (hydrate)		CK2, Ki: 20 nM CK2, IC₅₀: 40 nM
Casein kinase 1δ-IN-29	CKIδ, IC₅₀: 0.005 μM CK1ε, IC₅₀: 0.447 μM
Casein kinase 1δ-IN-4	CK1δ		≥98.0%
SR-4133	CK1ε, IC₅₀: 58 nM CK1δ, IC₅₀: 10 μM
CK2-IN-13		CK2, IC₅₀: 5.8 nM
Casein kinase 1δ-IN-3	CKIδ, pIC₅₀: 6.5376 M		99.93%
PIM-1/CK2-IN-2		CK2
Casein kinase 1δ-IN-10	CK1δ
MGD-28	CK1α, DC₅₀: 7.8 nM
TID43		CK2, IC₅₀: 0.3 μM
CK1-IN-3	CK1δ, IC₅₀: 2.22 μM		99.00%
CK2/PIM1-IN-1		CK2, IC₅₀: 3.787 μM
CK1-IN-4	CKIδ, IC₅₀: 2.74 μM
Casein kinase 1δ-IN-16	CKIδ
AMG-548 hydrochloride	CK1
SR-1277	CKIδ, IC₅₀: 49 nM
CK1δ-IN-3	CKIδ
Emodin (Standard)		CK2α Wild-type
CK2 inhibitor 4		CK2, IC₅₀: 3.8 μM
Casein kinase 1δ-IN-28	CK1ε, IC₅₀: 14.6 nM
EGFR-IN-57		CK2α, IC₅₀: 0.171 μM
Casein kinase 1δ-IN-15	CK1δ, IC₅₀: 0.045 μM
Multi-kinase-IN-6		CK2, IC₅₀: 0.09 μM
Casein kinase 1δ-IN-5	CK1δ, IC₅₀: 47 nM
Casein kinase 1δ-IN-17	CKIδ
Casein kinase 1δ-IN-18	CKIδ
HDAC/CK2-IN-1		CK2, IC₅₀: 3.67 μM
CK1δ-IN-9	CKIδ, IC₅₀: 1.4 nM
TMCB		CK2α, Ki: 83 nM CK2α', Ki: 21 nM
CK2 inhibitor 3		CK2, IC₅₀: 280 nM
Casein kinase 1δ-IN-31	CK1δ, IC₅₀: 17 nM CK1α, IC₅₀: 196 nM
p38α inhibitor 8	CK1δ, IC₅₀: 0.202 μM
4,5,6,7-Tetrabromo-1H-benzimidazole		CK2
CK2-IN-14		CK2, IC₅₀: 0.66 nM
CK2-IN-12		CK2, IC₅₀: 0.8 μM
WAY-606344	CK1δ
CSNK2-IN-2		CK2

Name
Email *

	Sorry, but the email address you supplied was invalid.

Casein Kinase

Casein Kinase

Casein Kinase Isoform Specific Products:

Casein Kinase Isoform Specific Products:

Casein Kinase Related Products (168)

Antibodies (5)

Casein Kinase Isoform Comparison

Casein Kinase Related Products (168):